Identifying Patients for Systemic Therapy: Beyond

Selecting the right patients for systemic therapy in alopecia areata requires moving beyond any single numeric threshold and into a more nuanced, individualized clinical assessment. Patients with limited, stable, localized disease may be well managed with topical corticosteroids, topical immunotherapy, or intralesional corticosteroid injections targeting discrete patches. These approaches are reasonable first-line options when disease burden is contained and the patient is not experiencing rapid progression. The clinical calculus shifts, however, when disease begins to evolve in ways that localized treatments cannot adequately address: SALT scores climbing within weeks rather than months, new patches appearing at previously uninvolved sites on the scalp or body, or intralesional injection sites multiplying in a "whack-a-mole" pattern where new lesions consistently outpace targeted treatment. At that point, continuing to chase individual patches with local therapies risks wasting time that could be spent arresting the disease systemically.

The SALT-50 enrollment criterion used in pivotal clinical trials served an important scientific function—

ensuring that trial populations had sufficient disease burden to

detect a meaningful treatment signal-but it does not translate directly into a clinical rule requiring practitioners to withhold systemic therapy until patients cross a specific threshold of scalp involvement. A patient losing 10% to 30% of scalp hair in discrete, rapidly expanding, psychologically distressing patches is, by any meaningful definition, experiencing a severe impact on quality of life. The dermatologist's role is to evaluate the full picture: pace of progression, functional impairment, emotional burden, and patient goals. Patient-reported outcomes-how frequently the individual thinks about their hair loss, whether they are avoiding work or social activities, whether they rely on hairpieces daily-carry genuine clinical weight and belong in the documentation.

Waiting for a patient at SALT-20 to reach SALT-50 before initiating systemic therapy is not conservative practice; it is a delay that narrows the window of best therapeutic response.

In this segment, Nader Aboul-Fettouh, MD, double board-certified dermatologist and fellowship-trained Mohs Micrographic Surgeon and founder and managing director of Blue Ribbon Dermatology in the Dallas area, explains his framework for evaluating patients as candidates for systemic therapy. He describes how he tracks the pace of disease progression, assesses functional and psychosocial impairment, and engages patients in shared decision-making conversations that center on their own goals and olerance for disease burden-rather than on a single population-derived scoring threshold that was designed for research, not clinical gatekeeping.